Alkermes, Biogen get diroximel fumarate for relapsing MS NDA accepted
Alkermes and Biogen said the FDA will check their novel oral fumarate in development for diroximel fumarate (BIIB098), for the treatment…
Pharmaceuticals, Biotechnology and Life Sciences
Alkermes and Biogen said the FDA will check their novel oral fumarate in development for diroximel fumarate (BIIB098), for the treatment…
Roche will fully buy Spark Therapeutics at a price of $114.50 per share in an all-cash transaction, or for $4.3…
Novartis will exercise its option for worldwide responsibility of TQJ230, an investigational agent for targeted cardiovascular therapy previously known as AKCEA-APO(a)-LRx, from Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals.
Taiho Oncology got aproval to have its Lonsurf as a treatment for adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma in the United States.
BioMarin Pharmaceutical’s net loss for 2018 decreased $39.8 million or 34%, to $77.2 million, compared to $117.0 million in 2017, in part due to increase in gross profil of million.
Mallinckrodt will drop testing its Therakos in the Phase 3 clinical trial for treating young patients with Steroid Refractory Acute Graft-versus-Host Disease, after the interim results were published.
Faron Pharmaceuticals said Thursday in a press release that it is currently opening two UK sites (London, Birmingham) to expand the Matins trial, following recent CTA approval by the UK regulator, the Medicines & Healthcare products Regulatory Agency (MHRA).
Torque will test its Deep IL-15 Primed T Cells (TRQ-1501) with Merck, both as a single agent and in combination with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in a Phase 1/2 study in multiple solid tumor indications.
Xencor has put on hold one of its studies on myeloid leukemia CD123 x CD3 bispecific antibody molecule XmAb14045, until the FDA lifts the hold, the company said Wednesday in a press release.
Alvogen has launched its generic equivalent to Indivior UK LLC’s Suboxone sublingual film (buprenorphine hydrochloride/naloxone hydrochloride) in the U.S.